191 related articles for article (PubMed ID: 15156163)
1. Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme.
Khan F; Agarwal A; Agrawal S
Bone Marrow Transplant; 2004 Jul; 34(1):1-12. PubMed ID: 15156163
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
[TBL] [Abstract][Full Text] [Related]
3. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of chimerism in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
Furukawa T; Hashimoto S; Inano K; Yamazaki F; Takeda H; Kakihara T; Yano T; Abe T; Higuchi W; Toba K; Takahashi M; Koike T; Aizawa Y
Rinsho Ketsueki; 2001 Jun; 42(6):488-95. PubMed ID: 11505528
[TBL] [Abstract][Full Text] [Related]
6. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
7. Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation.
Thiede C; Bornhäuser M; Ehninger G
Acta Haematol; 2004; 112(1-2):16-23. PubMed ID: 15179000
[TBL] [Abstract][Full Text] [Related]
8. [The clinical significance of interphase fluorescence in situ hybridization monitoring chimeric status after sex-mismatched allogeneic hematopoietic stem cell transplantation for leukemia].
Liu Q; Song L; Zhang Y; Wei Y; Xu D; Sun J; Liu X; Xu B; Meng F; Zhou S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Apr; 22(2):212-5. PubMed ID: 15793790
[TBL] [Abstract][Full Text] [Related]
9. FISH detection of chimerism in pediatric hematopoietic stem cell transplantation.
Aydin F; Oguz F; Onal AE; Bilgen H; Oguz R; Anak S; Carin M; Gedikoglu G
Int J Lab Hematol; 2007 Jun; 29(3):208-14. PubMed ID: 17474899
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of hematopoietic chimerism by quantitative real-time polymerase chain reaction of sequence polymorphism systems after hematopoietic stem cell transplantation.
Qin XY; Li GX; Qin YZ; Wang Y; Wang FR; Liu DH; Xu LP; Chen H; Han W; Wang JZ; Zhang XH; Li JL; Li LD; Liu KY; Huang XJ
Chin Med J (Engl); 2011 Aug; 124(15):2301-8. PubMed ID: 22029079
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease post-bone marrow transplantation for hemato-oncological diseases.
Toren A; Rechavi G; Nagler A
Stem Cells; 1996 May; 14(3):300-11. PubMed ID: 8724696
[TBL] [Abstract][Full Text] [Related]
12. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
13. Chimerism analysis following hematopoietic stem cell transplantation.
Murphy KM
Methods Mol Biol; 2013; 999():137-49. PubMed ID: 23666695
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
15. Microfluidic chip-based assay for post-hematopoietic stem cell transplantation chimerism monitoring using polymorphic tandem repeat markers.
Daud SS; Ibrahim K; Choong SS; Vengidasan L; Chong LA; Ariffin H
Anal Biochem; 2010 Feb; 397(2):181-5. PubMed ID: 19822126
[TBL] [Abstract][Full Text] [Related]
16. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
Huisman C; de Weger RA; de Vries L; Tilanus MG; Verdonck LF
Bone Marrow Transplant; 2007 Mar; 39(5):285-91. PubMed ID: 17262061
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
Pulsipher MA; Bader P; Klingebiel T; Cooper LJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):62-71. PubMed ID: 19147081
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning.
Shimoni A; Nagler A
Acta Haematol; 2004; 112(1-2):93-104. PubMed ID: 15179009
[TBL] [Abstract][Full Text] [Related]
19. Highly sensitive patient-specific real-time PCR SNP assay for chimerism monitoring after allogeneic stem cell transplantation.
Eshel R; Vainas O; Shpringer M; Naparstek E
Lab Hematol; 2006; 12(1):39-46. PubMed ID: 16513545
[TBL] [Abstract][Full Text] [Related]
20. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
